The link between female infertility and gynecological cancer has always been a debated and challenging topic. Although cervical cancer has the worst impact on female fertility, as it is usually diagnosed in patients of reproductive age, endometrial and ovarian cancer are also diagnosed and treated often in relatively younger patients in which fertility preservation is a relevant issue. The aim of this review is to highlight the correlation between therapy for female infertility and the developing cancer’s risk and to describe the fertility sparing treatments in gynecological oncology.
Material and methods:
A systematic review of the literature through the main scientific search engines (PubMed and Google Scholar) was performed. We selected the most relevant articles based on the largest case series and the latest updates. All selected documents have been listed in the references.
Results:
Fifty-six relevant articles published between 1996 and 2019 were identified.
Results from the available evidence report no significant increased risk of endometrial, cervical, and ovarian cancer in patients having infertility treatments.
In young patients diagnosed with gynecological cancer, preservation of fertility is a personalized choice depending on several factors (type, stage, age and desire to conceive, safety of the treatment, and feasibility of fertility sparing surgery). For ovarian cancer FIGO stage IA G1, IA G2 (grade), and IC G1; for endometrial adenocarcinoma grade 1 with no lymphovascular space invasion (LVSI) or myometrial invasion and for early-stage cervical cancer (FIGO stage 2018: IA1-IB1), fertility sparing treatment is possible. The role of fertility sparing treatment with the increase of personalization of therapies therapy is always a theme of discussion and research.
Conclusion:
At present data regarding the risk of gynecological cancers after infertility treatments are reassuring. Careful evaluation of female fertility-sparing options in young women interested by ovarian, endometrial, or cervical tumors should be carried out involving a multidisciplinary team and ensuring safety and efficacy.
Vander BorghtMWynsC. Fertility and infertility: definition and epidemiology. Clin Biochem2018; 62: 2–10.
2.
OmbeletW. Global access to infertility care in developing countries: a case of human rights, equity and social justice. Facts Views Vis Obgyn2011; 3(4): 257–266.
3.
BedoschiGNavarroPAOktayK. Chemotherapy-induced damage to ovary: mechanisms and clinical impact. Future Oncol2016; 12(20): 2333–2344.
4.
GadducciAAlettiGDLandoniF, et al. Management of ovarian cancer: guidelines of the Italian Medical Oncology Association (AIOM). Tumori2021; 107: 100.
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Ovarian cancer including fallopian tube cancer and primary peritoneal cancer. Version 1. NCCN.org.https://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf (2020, accessed 11 March 2020).
7.
ThonneauPMarchandSTallecA, et al. Incidence and main causes of infertility in a resident population (1 850 000) of three French regions (1988–1989). Hum Reprod1991; 6: 811–816.
8.
AliAT. Reproductive factors and the risk of endometrial cancer. Int J Gynecol Cancer2014; 24: 384–393.
9.
Practice Committee of the American Society for Reproductive Medicine. Fertility drugs and cancer: a guideline. Fertil Steril2016; 106: 1617–1626.
10.
WilliamsCLJonesMESwerdlowAJ, et al. Risks of ovarian, breast and corpus uteri cancer in women treated with assisted reproductive technology in Great Britain, 1991-2010: data linkage study including 2.2 million person years of observation. BMJ2018; 362: k2644.
11.
RischHA. Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. J Natl Cancer Inst1998; 90(23): 1774–1786.
12.
KonishiI. Gonadotropins and ovarian carcinogenesis: a new era of basic research and its clinical implications. Int J Gynecol Cancer2006; 16: 16–22.
13.
BoomsmaCMKavelaarsAEijkemansMJ, et al. Ovarian stimulation for in vitro fertilization alters the intrauterine cytokine, chemokine and growth factor milieu encountered by the embryo. Fertil Steril2010; 94: 1764–1768.
14.
GregoryCWWilsonEMApparaoKB, et al. Steroid receptor coactivator expression throughout the menstrual cycle in normal and abnormal endometrium. J Clin Endocrinol Metab2002; 87(6): 2960–2966.
DorJLerner-GevaLRabinoviciJ, et al. Cancer incidence in a cohort of infertile women who underwent in vitro fertilization. Fertil Steril2002; 77: 324–327.
17.
Lerner-GevaLRabinoviciJLunenfeldB. Ovarian stimulation: is there a long-term risk for ovarian, breast and endometrial cancer?Womens Health (Lond)2010; 6: 831–839.
18.
SiristatidisCSergentanisTNKanavidisP, et al. Controlled ovarian hyperstimulation for IVF: impact on ovarian, endometrial and cervical cancer: a systematic review and meta-analysis. Hum Reprod Update2013; 19(2): 105–123.
19.
TrabertBLambEJScocciaB, et al. Ovulation-inducing drugs and ovarian cancer risk: results from an extended follow-up of a large United States infertility cohort. Fertil Steril2013; 100(6): 1660–1666.
20.
KroenerLDumesicDAl-SafiZ. Use of fertility medications and cancer risk: a review and update. Curr Opin Obstet Gynecol2017; 29(4): 195–201.
21.
RizzutoIBehrensRFSmithLA. Risk of ovarian cancer in women treated with ovarian stimulating drugs for infertility (review). Cochrane Database Syst Rev2019; 6: CD008215. 6.
22.
LukeBBrownMBSpectorLG, et al. Cancer in women after assisted reproductive technology. Fertil Steril2015; 104: 1218–1226.
23.
van LeeuwenFEKlipHMooijTM, et al. Risk of borderline and invasive ovarian tumours after ovarian stimulation for in vitro fertilization in a large Dutch cohort. Hum Reprod2011; 26(12): 3456.
24.
SasoSLouisLSDoctorF, et al. Does fertility treatment increase the risk of uterine cancer? A meta-analysis. Eur J Obstet Gynecol Reprod Biol2015; 195: 52–60.
25.
BrintonLATrabertBShalevV, et al. in vitro fertilization and risk of breast and gynecologic cancers: a retrospective cohort study within the Israeli Maccabi Healthcare Services. Fertil Steril2013; 99: 1189–1196.
26.
ReigstadMMLarsenIKMyklebustTÅ, et al. Cancer risk among parous women following assisted reproductive technology. Hum Reprod2015; 30: 1952–1963.
27.
ReigstadMMStorengRMyklebustTÅ, et al. Cancer risk in women treated with fertility drugs according to parity status: a registry-based cohort study. Cancer Epidemiol Biomarkers Prev2017; 26(6): 953–962.
28.
KessousRDavidsonEMeirovitzM, et al. The risk of female malignancies after fertility treatments: a cohort study with 25-year follow-up. J Cancer Res Clin Oncol2016; 142: 287–293.
29.
Yli-KuhaANGisslerMKlemettiR, et al. Cancer morbidity in a cohort of 9175 Finnish women treated for infertility. Hum Reprod2012; 27: 1149–1155.
30.
Jane HenleySWardEMScottS, et al. Annual report to the nation on the status of cancer, part I: national cancer statistics. Cancer 2020; 126(10): 2225–2249.
AyhanATohmaYATuncM. Fertility preservation in early-stage endometrial cancer and endometrial intraepithelial neoplasia: a single-center experience. Taiwan J Obstet Gynecol2020; 59(3): 415–419.
33.
RamirezPTFrumovitzMBodurkaDC, et al. Hormonal therapy for the management of grade 1 endometrial adenocarcinoma: a literature review. Gynecol Oncol2004; 95: 133–138.
34.
KohWJGreerBEAbu-RustumNR, et al. Uterine neoplasms, version 1.2014. J Natl Compr Canc Netw2014; 12(2): 248–280.
35.
RodolakisABiliatisIMoriceP, et al. European Society of Gynecological Oncology task force for fertility preservation: clinical recommendations for fertility-sparing management in young endometrial cancer patients. Int J Gynecol Cancer2015; 25(7): 1258–1265.
36.
GreenwaldZRHuangLNWissingMD, et al. Does hormonal therapy for fertility preservation affect the survival of young women with early-stage endometrial cancer?Cancer2017; 123(9): 1545–1554.
37.
GundersonCCFaderANCarsonKA, et al. Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma: a systematic review. Gynecol Oncol2012; 125(2): 477–482.
38.
MasciulloVTrivellizziNZannoniG, et al. Prognostic impact of hysteroscopic resection of endometrial atypical hyperplasia/endometrioid intraepithelial neoplasia and early-stage cancer in combination with megestrol acetate. Am J Obstet Gynecol2021; 224: 408.
39.
JiaPZhangY. Ovarian preservation improves overall survival in young patients with early-stage endometrial cancer. Oncotarget2017; 8(35): 59940–59949.
40.
TestaGMcKennaGJGunbyRtJr, et al. First live birth after uterus transplantation in the United States. Am J Transplant2018; 18(5): 1270–1274.
41.
BentivegnaEMoricePUzanC, et al. Fertility-sparing surgery in epithelial ovarian cancer. Future Oncol2016; 12: 389–398.
42.
FotopoulouCBraicuISehouliJ. Fertility-sparing surgery in early epithelial ovarian cancer: a viable option?Obstet Gynecol Int2012; 2012: 238061.
43.
PalombaSFalboADel NegroS, et al. Ultra-conservative fertility-sparing strategy for bilateral borderline ovarian tumours: an 11-year follow-up. Hum Reprod2010; 25(8): 1966–1972.
44.
DaraïEFauvetRUzanC, et al. Fertility and borderline ovarian tumor: a systematic review of conservative management, risk of recurrence and alternative options. Hum Reprod Update2013; 19(2): 151–166.
45.
DittoAMartinelliFBoganiG, et al. Long-term safety of fertility sparing surgery in early stage ovarian cancer: comparison to standard radical surgical procedures. Gynecol Oncol2015; 138(1): 78–82.
46.
ZapardielIDiestroMDAlettiG. Conservative treatment of early stage ovarian cancer: oncological and fertility outcomes. Eur J Surg Oncol2014; 40(4): 387–393.
47.
MelamedARizzoAENiteckiR, et al. All-cause mortality after fertility-sparing surgery for stage I epithelial ovarian cancer. Obstet Gynecol2017; 130: 71–79.
48.
KajiyamaHShibataKMizunoM, et al. Long-term survival of young women receiving fertility-sparing surgery for ovarian cancer in comparison with those undergoing radical surgery. Br J Cancer2011; 105(9): 1288–1294.
49.
FruscioRCeppiLCorsoS, et al. Long-term results of fertility-sparing treatment compared with standard radical surgery for early-stage epithelial ovarian cancer. Br J Cancer2016; 115: 641. Br J Cancer 2016;115:641-8.
50.
SatohTHataeMWatanabeY, et al. Outcomes of fertility-sparing surgery for stage I epithelial ovarian cancer: a proposal for patient selection. J Clin Oncol2010; 28: 1727–1732.
51.
Ray-CoquardIMoricePLorussoD, et al. Non-epithelial ovarian cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol2018; 29Suppl 4: iv1.
52.
GallottaVGhezziFVizzaE, et al. Laparoscopic staging of apparent early stage ovarian cancer: results of a large, retrospective, multi-institutional series. Gynecol Oncol2014; 135(3): 428–434.
53.
GhezziFCromiAFanfaniF, et al. Laparoscopic fertility-sparing surgery for early ovarian epithelial cancer: a multi-institutional experience. Gynecol Oncol2016; 141: 461–465.
54.
GallottaVCiceroCConteC, et al. Robotic versus laparoscopic staging for early ovarian cancer: a case-matched control study. J Minim Invas Gynecol2017; 24(2): 293–298.
55.
CibulaDPötterRPlanchampF, et al. The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology guidelines for the management of patients with cervical cancer. Radiother Oncol2018; 127(3): 404–416.
56.
RamirezPTParejaRRendónGJ, et al. Management of low-risk early-stage cervical cancer: should conization, simple trachelectomy, or simple hysterectomy replace radical surgery as the new standard of care?Gynecol Oncol2014; 132(1): 254–259.
57.
SchmelerKMFrumovitzMRamirezPT. Conservative management of early stage cervical cancer: is there a role for less radical surgery?Gynecol Oncol2011; 120: 321–325.
58.
BentivegnaEGouySMaulardA, et al. Oncological outcomes after fertility-sparing surgery for cervical cancer: a systematic review. Lancet Oncol2016; 17(6): e240–e253.
59.
De VincenzoRRicciCFanfaniF, et al. Neoadjuvant chemotherapy followed by conization in stage IB2-IIA1 cervical cancer larger than 2 cm: a pilot study. Fertil Steril2021; 115(1): 148–156.
60.
PlanteMvan TrommelNLheureuxS, et al. FIGO 2018 stage IB2 (2-4 cm) cervical cancer treated with Neo-adjuvant chemotherapy followed by fertility sparing surgery (CONTESSA); Neo-Adjuvant chemotherapy and conservative surgery in cervical cancer to preserve fertility (NEOCON-F). A PMHC, DGOG, GCIG/CCRN and multicenter study. Int J Gynecol Cancer2019; 29(5): 969–975.
